Lupin gets USFDA nod for Rufinamide drugs USP

Lupin gets USFDA nod for Rufinamide drugs USP

by admin- Thursday, August 18th, 2022 03:39:25 PM

Global pharma major Lupin has obtained approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Rufinamide Tablets USP, a hundred mg, 200 mg, and four hundred mg, to market a common equal of Banzel® Tablets, one hundred mg, 200 mg, and four hundred mg, of Eisai Inc. The product could be synthetic at Lupin’s facility in Goa, India.

Rufinamide Tablets had envisioned annual sales of USD 164 million within the US.

News Updates